secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cabaletta Bio, Inc. (CABA)
CIK:        0001759138
Form:       8-K
Filed at:   2026-08-13T11:32:31+00:00
Accession:  0001759138-26-000038
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cabaletta Q2 2026: R&D $44.4M, cash $225.1M; rese-cel milestones on track
-------------------------------------------------------------------------

- R&D expenses $44.4M vs $37.6M in Q2 2025; G&A $7.6M vs $8.3M.
- Cash and investments $225.1M at June 30, 2026, up from $133.6M at Dec 31, 2025; funds ops into mid-2027.
- Registrational RESET-Myositis data on track for mid-2027; BLA submission planned 2H27 with juvenile data for Priority Review Voucher.
- SSc-associated ILD registrational cohort (~25 patients) to initiate 4Q26; PC-free approach incorporated in RESET-MG.
- ElevateBio selected as second CDMO alongside Lonza; 10-year supply agreement with Cellares announced April 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1759138/000175913826000038/0001759138-26-000038-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1759138/000175913826000038/caba-20260813.htm
  HTML page:      https://secwatch.observer/filing/0001759138-26-000038

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer